225 related articles for article (PubMed ID: 26460249)
21. Deficient CEBPA DNA binding function in normal karyotype AML patients is associated with favorable prognosis.
Fos J; Pabst T; Petkovic V; Ratschiller D; Mueller BU
Blood; 2011 May; 117(18):4881-4. PubMed ID: 21389317
[TBL] [Abstract][Full Text] [Related]
22. CCAAT/enhancer binding protein-alpha polymorphisms occur more frequently than mutations in acute myeloid leukemia and exist across all cytogenetic risk groups and leukemia subtypes.
Leecharendkeat A; Tocharoentanaphol C; Auewarakul CU
Int J Cancer; 2008 Nov; 123(10):2321-6. PubMed ID: 18729193
[TBL] [Abstract][Full Text] [Related]
23. Helicase-like transcription factor is a RUNX1 target whose downregulation promotes genomic instability and correlates with complex cytogenetic features in acute myeloid leukemia.
Cheng CK; Chan NP; Wan TS; Lam LY; Cheung CH; Wong TH; Ip RK; Wong RS; Ng MH
Haematologica; 2016 Apr; 101(4):448-57. PubMed ID: 26802049
[TBL] [Abstract][Full Text] [Related]
24. A copy number repeat polymorphism in the transactivation domain of the CEPBA gene is possibly associated with a protective effect against acquired CEBPA mutations: an analysis in 1135 patients with AML and 187 healthy controls.
Schnittger S; Bacher U; Eder C; Lohse P; Haferlach C; Kern W; Haferlach T
Exp Hematol; 2011 Jan; 39(1):87-94. PubMed ID: 20888888
[TBL] [Abstract][Full Text] [Related]
25. Mutations of CEBPA in acute myeloid leukemia FAB types M1 and M2.
Snaddon J; Smith ML; Neat M; Cambal-Parrales M; Dixon-McIver A; Arch R; Amess JA; Rohatiner AZ; Lister TA; Fitzgibbon J
Genes Chromosomes Cancer; 2003 May; 37(1):72-8. PubMed ID: 12661007
[TBL] [Abstract][Full Text] [Related]
26. Complexity of CEBPA dysregulation in human acute myeloid leukemia.
Pabst T; Mueller BU
Clin Cancer Res; 2009 Sep; 15(17):5303-7. PubMed ID: 19706798
[TBL] [Abstract][Full Text] [Related]
27. A clinical grade sequencing-based assay for CEBPA mutation testing: report of a large series of myeloid neoplasms.
Behdad A; Weigelin HC; Elenitoba-Johnson KS; Betz BL
J Mol Diagn; 2015 Jan; 17(1):76-84. PubMed ID: 25468431
[TBL] [Abstract][Full Text] [Related]
28. ID1 expression associates with other molecular markers and is not an independent prognostic factor in cytogenetically normal acute myeloid leukaemia.
Damm F; Wagner K; Görlich K; Morgan M; Thol F; Yun H; Delwel R; Valk PJM; Löwenberg B; Heuser M; Ganser A; Krauter J
Br J Haematol; 2012 Jul; 158(2):208-215. PubMed ID: 22568493
[TBL] [Abstract][Full Text] [Related]
29. CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations.
Fröhling S; Schlenk RF; Stolze I; Bihlmayr J; Benner A; Kreitmeier S; Tobis K; Döhner H; Döhner K
J Clin Oncol; 2004 Feb; 22(4):624-33. PubMed ID: 14726504
[TBL] [Abstract][Full Text] [Related]
30. GATA2 mutations are frequent in intermediate-risk karyotype AML with biallelic CEBPA mutations and are associated with favorable prognosis.
Fasan A; Eder C; Haferlach C; Grossmann V; Kohlmann A; Dicker F; Kern W; Haferlach T; Schnittger S
Leukemia; 2013 Feb; 27(2):482-5. PubMed ID: 22814295
[No Abstract] [Full Text] [Related]
31. CEBPA single mutation can be a possible favorable prognostic indicator in NPM1 and FLT3-ITD wild-type acute myeloid leukemia patients with intermediate cytogenetic risk.
Park SH; Chi HS; Cho YU; Jang S; Park CJ
Leuk Res; 2013 Nov; 37(11):1488-94. PubMed ID: 24054719
[TBL] [Abstract][Full Text] [Related]
32.
Mannelli F; Ponziani V; Bencini S; Bonetti MI; Benelli M; Cutini I; Gianfaldoni G; Scappini B; Pancani F; Piccini M; Rondelli T; Caporale R; Gelli AM; Peruzzi B; Chiarini M; Borlenghi E; Spinelli O; Giupponi D; Zanghì P; Bassan R; Rambaldi A; Rossi G; Bosi A
Haematologica; 2017 Mar; 102(3):529-540. PubMed ID: 28250006
[TBL] [Abstract][Full Text] [Related]
33. GATA2 zinc finger 1 mutations associated with biallelic CEBPA mutations define a unique genetic entity of acute myeloid leukemia.
Greif PA; Dufour A; Konstandin NP; Ksienzyk B; Zellmeier E; Tizazu B; Sturm J; Benthaus T; Herold T; Yaghmaie M; Dörge P; Hopfner KP; Hauser A; Graf A; Krebs S; Blum H; Kakadia PM; Schneider S; Hoster E; Schneider F; Stanulla M; Braess J; Sauerland MC; Berdel WE; Büchner T; Woermann BJ; Hiddemann W; Spiekermann K; Bohlander SK
Blood; 2012 Jul; 120(2):395-403. PubMed ID: 22649106
[TBL] [Abstract][Full Text] [Related]
34. Favorable prognosis of biallelic CEBPA gene mutations in acute myeloid leukemia patients: a meta-analysis.
Li HY; Deng DH; Huang Y; Ye FH; Huang LL; Xiao Q; Zhang B; Ye BB; Lai YR; Mo ZN; Liu ZF
Eur J Haematol; 2015 May; 94(5):439-48. PubMed ID: 25227715
[TBL] [Abstract][Full Text] [Related]
35. Characterization of CEBPA Mutations and Polymorphisms and their Prognostic Relevance in De Novo Acute Myeloid Leukemia Patients.
Sarojam S; Raveendran S; Vijay S; Sreedharan J; Narayanan G; Sreedharan H
Asian Pac J Cancer Prev; 2015; 16(9):3785-92. PubMed ID: 25987038
[TBL] [Abstract][Full Text] [Related]
36. Inactivation of the p53-KLF4-CEBPA Axis in Acute Myeloid Leukemia.
Seipel K; Marques MT; Bozzini MA; Meinken C; Mueller BU; Pabst T
Clin Cancer Res; 2016 Feb; 22(3):746-56. PubMed ID: 26408402
[TBL] [Abstract][Full Text] [Related]
37. MicroRNA let-7a-3 gene methylation is associated with karyotyping, CEBPA promoter methylation, and survival in acute myeloid leukemia.
Ko YC; Fang WH; Lin TC; Hou HA; Chen CY; Tien HF; Lin LI
Leuk Res; 2014 May; 38(5):625-31. PubMed ID: 24703161
[TBL] [Abstract][Full Text] [Related]
38. Capillary gel electrophoresis: a simple method for identification of mutations and polymorphisms in the CEBPA gene in patients with acute myeloid leukaemia.
Juhl-Christensen C; Bomberg M; Melsvik D; Hokland P; Nyvold CG
Eur J Haematol; 2008 Oct; 81(4):273-80. PubMed ID: 18616509
[TBL] [Abstract][Full Text] [Related]
39. Detection of CEBPA double mutants in acute myeloid leukemia using a custom gene expression array.
van Vliet MH; Burgmer P; de Quartel L; Brand JP; de Best LC; Viëtor H; Löwenberg B; Valk PJ; van Beers EH
Genet Test Mol Biomarkers; 2013 May; 17(5):395-400. PubMed ID: 23485358
[TBL] [Abstract][Full Text] [Related]
40. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.
Schlenk RF; Döhner K; Krauter J; Fröhling S; Corbacioglu A; Bullinger L; Habdank M; Späth D; Morgan M; Benner A; Schlegelberger B; Heil G; Ganser A; Döhner H;
N Engl J Med; 2008 May; 358(18):1909-18. PubMed ID: 18450602
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]